Citing data from Cohort 1 in its ELIMINATE-B Phase 1 dose-finding study, Precision (NASDAQ:DTIL) said PBGENE-HBV was found to be safe and well tolerated in the first three participants who ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.